Tanikawa et al. study has been informative & further declarative research is needed yet shows Degradative Effect of Nattokinase (NATTO) on Spike Protein of SARS-CoV-2; results extrapolated to vaccine

These results along with others show that NATTO can degrade the spike protein & thus those afflicted with the toxic effects of the mRNA technology based gene injection spike (& virus) have help

SOURCE:

https://pubmed.ncbi.nlm.nih.gov/36080170/

‘Nattokinase is produced by Bacillus subtilis var. natto and is beneficial to human health. In this study, we examined the effect of nattokinase on the S protein of SARS-CoV-2. When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.’

READ here for consideration and to become more informed on NATTO etc.

SOURCE:

https://www.twc.health/products/long-haul-formula?ref=Paul

The Wellness Company (TWC) has a product called ‘Spike Recovery’ that comprises NATTO and these products should be considered to battle harmful effects e.g. clotting, of the virus and mRNA gene shot. Yes, the science is maturing but people need help now with safe formulations and NATTO etc. are natural fibrinolytics (blood thinners). Spike Recovery is safe, cheap, effective and may give the help needed. Those breast feeding, pregnant, on blood thinners, and persons under 18 should not use any supplement or drug unless cleared/discussed with their physician.

SOURCE:

https://www.twc.health/products/long-haul-formula?ref=Paul

See additional related research:

• The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.

  Musarrat F, et al. J Med Virol. 2020. PMID: 32374457 Free PMC article.

• The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.

  Li K, et al. mBio. 2021. PMID: 34340553 Free PMC article.

• Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.

  Day CJ, et al. mBio. 2021. PMID: 33785634 Free PMC article.

• Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.

  Acharya A, et al. J Virol. 2021. PMID: 34550770 Free PMC article.

• Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.

  Muralidar S, et al. J Med Virol. 2021. PMID: 33851732 Free PMC article. Review.